

FIGURE 1




FIGURE 2




FIGURE 3A

Effect of Local Compound on OHC Loss Caused by Neomycin






FIGURE 3B



*** p<0.0001, t test

FIGURE 3C



*** p<0.0001, t test

FIGURE 4A

Neomycin+Compound (10ng) or Neomycin+Vehicle
Applied to Round Windows




FIGURE 4B

**Neomycin and Compound (1ng) or Vehicle
Applied to Round Window**




FIGURE 5
Effect of Subcutaneous Compound
on OHC Loss Caused by Neomycin




FIGURE 6

Neomycin Applied to Round Window, Vehicle
or Compound Administered via S.C. Injection

■ vehicle s.c. injection (n=9)
▨ Compound s.c. injection (n=10)




FIGURE 7






FIGURE 8

Neomycin and Compound (10 ng) or
Vehicle Applied to Round Window



*** p<0.001, t test


FIGURE 9



** p<0.01, † test

FIGURE 10

Neomycin and Compound (10 ng) or Vehicle
Applied to Round Window






Figure 11




Figure 12